A photo of Theodosia A. Kalfa.

Theodosia A. Kalfa, MD, PhD


  • Co-Director, Erythrocyte Diagnostic Laboratory
  • Professor, UC Department of Pediatrics

About

Additional Languages

Greek

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. American Journal of Human Genetics. 2020; 107:1149-1156.

Selected

Red cell membrane disorders: structure meets function. Risinger, M; Kalfa, TA. Blood. 2020; 136:1250-1261.

Selected

Signaling and cytoskeletal requirements in erythroblast enucleation. Konstantinidis, DG; Pushkaran, S; Johnson, JF; Cancelas, JA; Manganaris, S; Harris, CE; Williams, DA; Zheng, Y; Kalfa, TA. Blood. 2012; 119:6118-6127.

Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. Noomuna, P; Hausman, JM; Sansoya, R; Kalfa, T; Risinger, M; Low, PS. FASEB Journal. 2022; 36.

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Forsyth, S; Schroeder, P; Geib, J; Vrishabhendra, L; Konstantinidis, DG; LaSalvia, K; Ribadeneira, MD; Wu, E; Kelly, P; Kalfa, TA. Clinical Pharmacology in Drug Development. 2022; 11:654-665.

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Schroeder, P; Fulzele, K; Forsyth, S; Ribadeneira, MD; Guichard, S; Wilker, E; Marshall, CG; Drake, A; Fessler, R; Konstantinidis, DG; et al. Journal of Pharmacology and Experimental Therapeutics. 2022; 380:210-219.

eP420: Clinical utility of a 38-gene NGS panel in diagnosing patients with hemolytic anemia: A retrospective review of 435 cases. Hu, X; Wang, X; Guan, Q; Wu, Y; Liu, J; Dawson, B; Kalfa, T; Zhang, W. Genetics in Medicine. 2022; 24.

Altered erythropoiesis in newborns with congenital heart disease. Tseng, SY; Gao, Z; Kalfa, TA; Ollberding, NJ; Tabbah, S; Keller, R; Cnota, JF. Pediatric Research. 2022; 91:606-611.

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. Lal, A; Brown, C; Coates, T; Kalfa, T; Kwiatkowski, JL; Brevard, J; Trenor, C; Wood, K; Sheth, S. HemaSphere. 2022; 6.

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS. Telen, M; Saraf, S; Cruz, K; Idowu, M; Kalfa, T; Osunkwo, I; Hagar, R; Geib, J; Forsyth, S; Schroeder, P; et al. HemaSphere. 2022; 6:5-5.

From the Blog



Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey